PL2928898T3 - Inhibitory beta-laktamaz - Google Patents

Inhibitory beta-laktamaz

Info

Publication number
PL2928898T3
PL2928898T3 PL13861198T PL13861198T PL2928898T3 PL 2928898 T3 PL2928898 T3 PL 2928898T3 PL 13861198 T PL13861198 T PL 13861198T PL 13861198 T PL13861198 T PL 13861198T PL 2928898 T3 PL2928898 T3 PL 2928898T3
Authority
PL
Poland
Prior art keywords
beta
lactamase inhibitors
lactamase
inhibitors
Prior art date
Application number
PL13861198T
Other languages
English (en)
Polish (pl)
Inventor
Christopher J. Burns
Denis Daigle
Bin Liu
Daniel Mcgarry
Daniel C. Pevear
Robert E. Lee TROUT
Original Assignee
VenatoRx Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VenatoRx Pharmaceuticals, Inc. filed Critical VenatoRx Pharmaceuticals, Inc.
Publication of PL2928898T3 publication Critical patent/PL2928898T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
PL13861198T 2012-12-07 2013-12-05 Inhibitory beta-laktamaz PL2928898T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261734900P 2012-12-07 2012-12-07
US201361783238P 2013-03-14 2013-03-14
EP13861198.3A EP2928898B1 (en) 2012-12-07 2013-12-05 Beta-lactamase inhibitors
PCT/US2013/073428 WO2014089365A1 (en) 2012-12-07 2013-12-05 Beta-lactamase inhibitors

Publications (1)

Publication Number Publication Date
PL2928898T3 true PL2928898T3 (pl) 2021-10-25

Family

ID=50884012

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13861198T PL2928898T3 (pl) 2012-12-07 2013-12-05 Inhibitory beta-laktamaz

Country Status (16)

Country Link
US (6) US9422314B2 (he)
EP (2) EP3922635A1 (he)
JP (2) JP6403219B2 (he)
KR (1) KR102147420B1 (he)
CN (1) CN105026407B (he)
AU (1) AU2013355110B2 (he)
BR (1) BR112015013123B1 (he)
CA (1) CA2893943C (he)
ES (1) ES2878118T3 (he)
HR (1) HRP20210879T1 (he)
IL (1) IL239212B (he)
PL (1) PL2928898T3 (he)
PT (1) PT2928898T (he)
RU (1) RU2654692C2 (he)
WO (1) WO2014089365A1 (he)
ZA (1) ZA201504200B (he)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013003045B1 (pt) 2010-08-10 2021-08-31 Rempex Pharmaceuticals, Inc. Composto e respectivo uso, composição farmacêutica, recipiente estéril e método para preparar composição farmacêutica para administração
US9012491B2 (en) 2011-08-31 2015-04-21 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
KR102147420B1 (ko) 2012-12-07 2020-08-25 베나토알엑스 파마슈티컬스, 인크. 베타-락타마제 억제제
MX2015008627A (es) 2013-01-04 2015-09-23 Rempex Pharmaceuticals Inc Derivados de acido boronico y usos terapeuticos de los mismos.
CA2894891A1 (en) * 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2014110442A1 (en) 2013-01-10 2014-07-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
EP2970340B1 (en) 2013-03-14 2020-02-12 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
RS59488B1 (sr) 2014-05-05 2019-12-31 Rempex Pharmaceuticals Inc Sinteza boronatnih soli i njihove upotrebe
US9687497B1 (en) 2014-05-05 2017-06-27 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
KR20170007448A (ko) * 2014-05-19 2017-01-18 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
KR102396753B1 (ko) 2014-06-11 2022-05-12 베나토알엑스 파마슈티컬스, 인크. 베타-락타마제 억제제
US20150361108A1 (en) * 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Orally bioavailable beta-lactamase inhibitors
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
EP3164406B1 (en) * 2014-07-01 2024-12-25 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
CN107207537B (zh) 2014-12-19 2019-05-31 莱姆派克斯制药公司 用于生产硼酸衍生物的设备和连续流方法
CA2971763A1 (en) 2014-12-23 2016-06-30 Bergenbio Asa Inhibitors of akt kinase
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EP3347008B1 (en) 2015-09-11 2022-03-09 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN105801610B (zh) * 2016-04-19 2018-05-18 武汉维舜医药科技有限公司 新型广谱β-内酰胺酶抑制剂
US10294249B2 (en) 2016-06-30 2019-05-21 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2018027062A1 (en) 2016-08-04 2018-02-08 VenatoRx Pharmaceuticals, Inc. Boron-containing compounds
GB201613946D0 (en) 2016-08-15 2016-09-28 Univ Oslo Compounds
PL3592362T3 (pl) * 2017-03-06 2025-06-23 VenatoRx Pharmaceuticals, Inc. Postacie stałe i kompozycje skojarzone zawierające inhibitor beta-laktamaz i ich zastosowania
WO2018199291A1 (ja) * 2017-04-28 2018-11-01 大日本住友製薬株式会社 ヘテロ環誘導体
GB201708002D0 (en) 2017-05-18 2017-07-05 Univ Oxford Innovation Ltd ß-Lactamase inhibitors
US11332485B2 (en) 2017-05-26 2022-05-17 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
US11267826B2 (en) 2017-05-26 2022-03-08 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
US11286270B2 (en) 2017-10-11 2022-03-29 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis thereof
CN118388347A (zh) * 2017-11-01 2024-07-26 梅琳塔治疗公司 化合物、由其形成的硼酸酯衍生物及其制备方法
EP3781576B1 (en) 2018-04-20 2024-06-12 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
UA129150C2 (uk) 2018-04-27 2025-01-29 Сумітомо Фарма Ко., Лтд. Оксозаміщена сполука
WO2019226931A1 (en) 2018-05-25 2019-11-28 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
WO2020056048A1 (en) 2018-09-12 2020-03-19 VenatoRx Pharmaceuticals, Inc. Combination compositions comprising a beta-lactamase inhibitor
KR20210146979A (ko) * 2019-04-02 2021-12-06 베나토알엑스 파마슈티컬스, 인크. 경구 전달 베타-락타마제 억제제의 고체 형태 및 이의 용도
CA3155559A1 (en) 2019-10-25 2021-04-29 Sachiko Koike Novel substituted condensed ring compound
JP7550421B2 (ja) * 2019-10-25 2024-09-13 住友ファーマ株式会社 オキソ置換化合物からなる医薬
US11058695B2 (en) * 2019-11-08 2021-07-13 Myongji University Industry And Academia Cooperation Foundation Inhibitor of carbapenem-hydrolyzing class D beta-lactamases
TW202128718A (zh) 2019-11-26 2021-08-01 美商維納拓爾斯製藥公司 青黴素結合蛋白抑制劑
EP4201942A4 (en) * 2020-08-20 2024-08-21 Phaeno Therapeutics Co., Ltd. BORACIC ACID COMPOUND
TW202228720A (zh) * 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
WO2022187362A1 (en) * 2021-03-02 2022-09-09 Case Western Reserve University Β-lactamase inhibitors and uses thereof
MX2023012004A (es) 2021-04-13 2023-10-20 Tuojie Biotech Shanghai Co Ltd DERIVADO DEL ÁCIDO BÓRICO QUE ACTÚA COMO INHIBIDOR DE LA ß-LACTAMASA.
WO2023155869A1 (zh) * 2022-02-18 2023-08-24 辉诺生物医药科技（杭州）有限公司 新的硼酸类化合物的晶型及其制备方法
GB202306835D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE41109B1 (en) 1974-04-20 1979-10-24 Beecham Group Ltd Novel -lactam antibiotic from streptomyces clavuligerus
IT1283467B1 (it) * 1996-07-19 1998-04-21 Menarini Farma Ind Derivati di cicloalcani 1,2 sostituiti come inibitori della trombina, procedimento per la loro preparazione e loro impiego in formulazioni
DE60004685T2 (de) 1999-09-17 2004-07-29 Abbott Gmbh & Co. Kg Pyrazolopyrimidine als arzneimittel
US7271186B1 (en) * 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors
EP1635812A2 (en) 2003-06-10 2006-03-22 Fulcrum Pharmaceuticals, Inc. Beta-lactamase inhibitors and methods of use thereof
ES2899606T3 (es) 2004-03-30 2022-03-14 Millennium Pharm Inc Síntesis de compuestos de ésteres y ácidos borónicos
CN1965838A (zh) 2005-11-17 2007-05-23 李海超 含头孢匹胺和β－内酰胺酶抑制剂的药物组合物
SI1965798T1 (sl) 2005-12-07 2012-01-31 Basilea Pharmaceutica Ag Uporabni monobaktamski antibiotiki
CN101129382B (zh) 2006-08-25 2013-12-25 天津和美生物技术有限公司 含β-内酰胺类抗生素和缓冲组分的抗生素复方
BRPI0820531A2 (pt) * 2007-11-13 2012-07-10 Protez Pharmaceuticals Inc inibidores de beta-lactamase
US20100120715A1 (en) 2007-11-13 2010-05-13 Burns Christopher J Beta-lactamase inhibitors
SI2231667T1 (sl) * 2008-01-18 2013-12-31 Merck Sharp & Dohme Corp. Beta laktamazni inhibitorji
US20100292185A1 (en) * 2009-05-12 2010-11-18 Burns Christopher J Beta-lactamase inhibitors
WO2011017125A1 (en) 2009-07-28 2011-02-10 Anacor Pharmaceuticals, Inc. Trisubstituted boron-containing molecules
BR112013003045B1 (pt) * 2010-08-10 2021-08-31 Rempex Pharmaceuticals, Inc. Composto e respectivo uso, composição farmacêutica, recipiente estéril e método para preparar composição farmacêutica para administração
EP2768503A1 (en) 2011-07-26 2014-08-27 Wockhardt Limited Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor
SG10201601327RA (en) 2011-09-04 2016-03-30 Glytech Inc Glycosylated polypeptide and drug composition containing said polypeptide
WO2013053372A1 (en) 2011-10-13 2013-04-18 Therabor Pharmaceuticals Boronic acid inhibitors of beta-lactamases
KR101288157B1 (ko) 2011-12-07 2013-07-19 백병하 기존 세파계 항생제 및 베타 락타마제 저해제로 배합된 내성균주에 기인한 감염증의 치료 및 예방을 위한 복합항생제
EA201400735A1 (ru) 2011-12-22 2015-04-30 Арес Трейдинг С.А. Производные альфа-амино бороновой кислоты, селективные ингибиторы иммунопротеасомы
US20150119363A1 (en) 2012-02-15 2015-04-30 Rempex Pharmaceuticals, Inc.. Methods of treating bacterial infections
CN104822689B (zh) 2012-12-03 2016-11-02 弗·哈夫曼-拉罗切有限公司 取代的三唑硼酸化合物
KR102147420B1 (ko) 2012-12-07 2020-08-25 베나토알엑스 파마슈티컬스, 인크. 베타-락타마제 억제제
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CA2894891A1 (en) 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
MX2015008627A (es) 2013-01-04 2015-09-23 Rempex Pharmaceuticals Inc Derivados de acido boronico y usos terapeuticos de los mismos.
WO2014110442A1 (en) 2013-01-10 2014-07-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
EP2970340B1 (en) 2013-03-14 2020-02-12 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2015051101A1 (en) 2013-10-02 2015-04-09 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
WO2015157618A1 (en) 2014-04-11 2015-10-15 The Texas A&M University System Novel inhibitors of the new delhi metallo beta lactamase (ndm-1)
KR20170007448A (ko) 2014-05-19 2017-01-18 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
KR102396753B1 (ko) 2014-06-11 2022-05-12 베나토알엑스 파마슈티컬스, 인크. 베타-락타마제 억제제
US20150361107A1 (en) * 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Orally bioavailable beta-lactamase inhibitors
US20150361108A1 (en) 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Orally bioavailable beta-lactamase inhibitors
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
JP6218204B2 (ja) 2014-09-04 2017-10-25 塩野義製薬株式会社 カテコール基を有するセファロスポリン類を含有する製剤
CN107207537B (zh) 2014-12-19 2019-05-31 莱姆派克斯制药公司 用于生产硼酸衍生物的设备和连续流方法
EP3347008B1 (en) 2015-09-11 2022-03-09 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN105801610B (zh) 2016-04-19 2018-05-18 武汉维舜医药科技有限公司 新型广谱β-内酰胺酶抑制剂
WO2018027062A1 (en) 2016-08-04 2018-02-08 VenatoRx Pharmaceuticals, Inc. Boron-containing compounds
PL3592362T3 (pl) 2017-03-06 2025-06-23 VenatoRx Pharmaceuticals, Inc. Postacie stałe i kompozycje skojarzone zawierające inhibitor beta-laktamaz i ich zastosowania
US11332485B2 (en) 2017-05-26 2022-05-17 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
US11267826B2 (en) 2017-05-26 2022-03-08 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
US11247965B2 (en) 2017-12-11 2022-02-15 VenatoRx Pharmaceuticals, Inc. Hepatitis B capsid assembly modulators
WO2019226931A1 (en) 2018-05-25 2019-11-28 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors

Also Published As

Publication number Publication date
CA2893943A1 (en) 2014-06-12
US10669290B2 (en) 2020-06-02
CN105026407B (zh) 2017-09-08
US20160326189A1 (en) 2016-11-10
US20150291630A1 (en) 2015-10-15
EP2928898A1 (en) 2015-10-14
AU2013355110B2 (en) 2017-11-09
EP2928898A4 (en) 2016-06-29
EP2928898B1 (en) 2021-04-14
PT2928898T (pt) 2021-07-05
IL239212B (he) 2019-10-31
IL239212A0 (he) 2015-07-30
HRP20210879T1 (hr) 2021-08-20
KR20150109348A (ko) 2015-10-01
RU2015126912A (ru) 2017-01-12
AU2013355110A1 (en) 2015-07-02
CN105026407A (zh) 2015-11-04
US20140171390A1 (en) 2014-06-19
BR112015013123A2 (pt) 2017-07-11
KR102147420B1 (ko) 2020-08-25
HK1217334A1 (zh) 2017-01-06
ES2878118T3 (es) 2021-11-18
US8912169B2 (en) 2014-12-16
US9422314B2 (en) 2016-08-23
CA2893943C (en) 2021-03-02
JP6403219B2 (ja) 2018-10-10
US9828391B2 (en) 2017-11-28
ZA201504200B (en) 2017-09-27
RU2654692C2 (ru) 2018-05-22
BR112015013123B1 (pt) 2021-02-17
US20190225628A1 (en) 2019-07-25
US10214547B2 (en) 2019-02-26
US20180194783A1 (en) 2018-07-12
US20250236632A1 (en) 2025-07-24
WO2014089365A1 (en) 2014-06-12
JP2016502973A (ja) 2016-02-01
JP2018184409A (ja) 2018-11-22
EP3922635A1 (en) 2021-12-15

Similar Documents

Publication Publication Date Title
ZA201504200B (en) Beta-lactamase inhibitors
EP2970340A4 (en) BETA-Lactamase INHIBITORS
EP2943204A4 (en) BETA-Lactamase INHIBITORS
SI2892889T1 (sl) Inhibitorske spojine
SG11201405965RA (en) Heterobicyclic compounds as beta-lactamase inhibitors
IL234845A0 (he) איזוקאסזול כמעכבי בטא לקטומאז
ZA201506156B (en) Novel inhibitors
LT2838888T (lt) Tiadiazolidindionai kaip gsk-3 inhibitoriai
IL238391A (he) מעכבי rock
IL239153A0 (he) פירידופירזין תחליפי כמעכב
IL235919A0 (he) מעכבים של fbxo3
PL2912021T3 (pl) Inhibitory agrekanazy
EP2885291A4 (en) INHIBITORS OF VEGFR3
EP2885292A4 (en) VEGFR3 INHIBITORS
PL2888228T3 (pl) Inhibitory oddziaływania CD40-TRAF6
GB201211019D0 (en) Inhibitor compounds
GB201223308D0 (en) Enzyme inhibitors
GB201210390D0 (en) Antibacterial enzyme inhibitors
GB201200094D0 (en) Antibacterial enzyme inhibitors
GB201120474D0 (en) Inhibitors